OGS Appoints Donald W. DeGolyer to Main Board as President of Global Therapeutics
OXFORD, UK, March 5 /PRNewswire-FirstCall/ -- Oxford GlycoSciences Plc (LSE: OGS, Nasdaq: OGSI) announced today that it has appointed Don DeGolyer to the OGS Board of Directors as President of Global Therapeutics with immediate effect. Don joined OGS in September 2001 to lead the commercialisation of OGS' drug products, including its lead compound Vevesca (OGT 918), an oral treatment for type 1 Gaucher disease, which is currently undergoing regulatory review. Prior to joining OGS, Don spent 16 years with Pfizer and Johnson & Johnson where he was Vice President of Marketing and Sales. Commenting on the appointment, Kirk Raab, Chairman of OGS said, "Don has already made a substantial contribution to OGS through his leadership of Global Therapeutics and I am delighted to welcome him to the main Board." Notes to Editors OGS has developed a patented technology platform in the emerging field of proteomics, the comprehensive study of proteins, integrating proteomics with genomics to create an innovative drug discovery platform. OGS' proteomics collaborations with major pharmaceutical and biotechnology companies include Bayer, Pioneer Hi-Bred/DuPont, Medarex/GenMab, GlaxoSmithKline, NeoGenesis and Pfizer. OGS has technology development collaborations with Applera, Cambridge Antibody Technology, Packard BioScience and the Institute for Systems Biology. OGS has also entered into a joint venture, Confirmant Limited, to develop the Protein Atlas of the Human Genome(TM). OGS has drug research discovery programmes in central nervous system, cancer, infectious disease and glycosphingolipid (GSL) storage disorders. OGS has had submissions to regulatory authorities accepted for review in both Europe and the US for its development compound, Vevesca (OGT 918), for the treatment of type 1 Gaucher disease. This release contains forward-looking statements, such as the commercial potential and success of OGS' collaborations and drug candidates. Factors that could cause actual results to vary significantly from those expressed or implied by these and other forward-looking statements include the success of OGS' research and development strategies, the validity of its technologies and intellectual property position and strategies, the medical conclusions on which Vevesca (OGT 918) is based and uncertainties related to the regulatory process. Vevesca (OGT 918) is an investigational drug and has not received approval for marketing in any country. For further information please contact: Oxford GlycoSciences Plc Michael Kranda, Chief Executive Officer Dr Stephen Parker, Chief Financial Officer Tel: +44 (0) 1235 208000 WorldWide Web: www.ogs.com UK: Financial Dynamics Melanie Toyne Sewell/Sarah Mehanna Tel: +44 (0) 20 7831 3113 +44 (0) 20 7269 7236 USA: Feinstein Kean Michelle Linn/Michael Lawson Tel: +1 (617) 761 6765 +1 (617) 577 8110 MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X78237165
SOURCE Oxford GlycoSciences Plc
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.